M. Lassus
Impact in
- Cancer Research top 2%
- Breast Cancer Treatment Studies
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
Papers in
- Genetics 5
- Estrogen and related hormone effects 5
-
- Chemotherapy-induced organ toxicity mitigation 1
- Systemic Sclerosis and Related Diseases 1
- Co-authors
- Matthew J. Ellis (1 shared paper)J. Eremin (1 shared paper)Margaret Dugan (1 shared paper)W. Eiermann (1 shared paper)Antonio Llombart‐Cussac (1 shared paper)Semiglazov Vf (1 shared paper)J. Vinholes (1 shared paper)Stefan Paepke (1 shared paper)
- Journals
- Annals of Oncology (4 papers)Journal of Clinical Oncology (3 papers)European Journal of Cancer (2 papers)Investigational New Drugs (1 paper)The Prostate (1 paper)
- Partner nations
- SwitzerlandUnited KingdomGermany
In The Last Decade
M. Lassus
18 papers receiving 1.2k citations
M. Lassus's Hit Papers
Peers
Comparison fields: 5 of 78
- Cancer Research 563
- Oncology 560
- Genetics 569
- Toxicology 28
- Pathology and Forensic Medicine 127
Countries citing papers authored by M. Lassus
This map shows the geographic impact of M. Lassus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lassus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lassus more than expected).
Fields of papers citing papers by M. Lassus
This network shows the impact of papers produced by M. Lassus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lassus. The network helps show where M. Lassus may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Lassus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Hit paper breakdown → | 2001 | 533 |
| 2 | 1998 | 205 | |
| 3 | Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. | 1992 | 129 |
| 4 | 1992 | 75 | |
| 5 | 1997 | 64 | |
| 6 | 1985 | 54 | |
| 7 | 2004 | 49 | |
| 8 | 1992 | 42 | |
| 9 | 1994 | 41 | |
| 10 | 1985 | 40 | |
| 11 | 1984 | 26 | |
| 12 | 2000 | 24 | |
| 13 | 2017 | 9 | |
| 14 | 2020 | 7 | |
| 15 | 2018 | 4 | |
| 16 | 2022 | 2 | |
| 17 | 1998 | 2 | |
| 18 | [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. | 1999 | 1 |
| 19 | 2024 | 0 | |
| 20 | 2013 | 0 |
About M. Lassus
M. Lassus is a scholar working on Genetics, Pathology and Forensic Medicine, Cardiology and Cardiovascular Medicine, Oncology and Obstetrics and Gynecology, having authored 20 papers that have together received 1.3k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (5 papers), Chemotherapy-induced cardiotoxicity and mitigation (2 papers), Pregnancy and preeclampsia studies (2 papers), Breast Cancer Treatment Studies (2 papers), Chemotherapy-induced organ toxicity mitigation (1 paper), Chronic Myeloid Leukemia Treatments (1 paper), Systemic Sclerosis and Related Diseases (1 paper) and Cardiac, Anesthesia and Surgical Outcomes (1 paper). The work is most often cited by research in Cancer Research (563 citations), Oncology (560 citations), Genetics (569 citations), Toxicology (28 citations) and Pathology and Forensic Medicine (127 citations). M. Lassus has collaborated with scholars based in Switzerland, United Kingdom and Germany. Frequent co-authors include Matthew J. Ellis, J. Eremin, Margaret Dugan, W. Eiermann, Antonio Llombart‐Cussac, Semiglazov Vf, J. Vinholes, Stefan Paepke, Hilary A. Chaudri‐Ross and L. Mauriac. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, Investigational New Drugs and The Prostate.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.